Skip to main content

Goldman Sachs Keeps Their Buy Rating on Novo Nordisk (0QIU)

Tipranks - Tipranks - Tue Feb 24, 5:56AM CST

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk, with a price target of DKK400.00.

Claim 50% Off TipRanks Premium

According to TipRanks, Quigley is an analyst with an average return of -7.2% and a 39.49% success rate. Quigley covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Sanofi, and Roche Holding AG.

In addition to Goldman Sachs, Novo Nordisk also received a Buy from Kepler Capital ‘s David Evans in a report issued on February 19. However, on February 17, Barclays maintained a Hold rating on Novo Nordisk (LSE: 0QIU).

See the top stocks recommended by analysts >>

0QIU market cap is currently DKK1383.4B and has a P/E ratio of 13.50.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of 0QIU in relation to earlier this year.

Read More on GB:0QIU:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).